Skip to content
21+ onlyResearch-grade peptidesExternal reports listed where availableDelivery £20Free delivery on orders of £300 or more10% off merchandise with crypto
Cognitive & Neuropeptide6 min readPublished 8 August 2026Reviewed 8 August 2026

Semax and Selank in neuropeptide research models

What enzyme, gene-expression and animal-learning studies can—and cannot—show.

Apex Pharma Research

Semax and Selank are synthetic regulatory peptides investigated in several mechanistic settings. Published work includes serum peptidase assays, gene-expression experiments and animal behavioural models.

For Semax, one rat study reported changes in BDNF expression across brain regions. Selank has been studied in conditioned-avoidance experiments in rats. Neither result should be rewritten as a guaranteed cognitive or mood benefit.

ADAMAX is listed separately as an Adamax (Semax analogue) product identity supplied by the owner. That identity does not make Semax study results directly applicable to Adamax.

References

  1. Semax and Selank inhibit the enkephalin-degrading enzymes from human serum ↗
  2. The heptapeptide SEMAX stimulates BDNF expression in rat brain areas ↗
  3. The optimizing action of Selank in a conditioned avoidance reflex in rats ↗

Research use only. All products described on this site are for laboratory research purposes. They are not medicines and are not intended to diagnose, treat, cure or prevent any disease.